This article is more than 5 years old. Information may no longer be current.

Abbott finalizes purchase of OptiMedica

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Abbott has completed its entry into the femtosecond laser-assisted cataract surgery market with the completion of its acquisition of OptiMedica, the company said in a news release.

“OptiMedica’s technology, combined with Abbott’s global market presence, offer the potential to provide advanced cataract treatment options to more patients around the world,” Murthy Simhambhatla, PhD, senior vice president of Abbott Medical Optics, said in the release.

While most cataract surgeries involve the surgeon making manual incisions, the Catalys Precision Laser System from OptiMedica — which already has CE mark approval in Europe and clearance from the U.S. Food and Drug Administration — is designed to allow for more precise anterior capsulotomy, phacofragmentation and other incisions, the release said.

Abbott’s transaction with OptiMedica, announced in mid-July, was made for $250 million cash. Up to $150 million more may be exchanged based on completion of certain development, regulatory and sales milestones, according to the release.